{"name":"Kures, Inc.","slug":"kures-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OxyNorm","genericName":"OxyNorm","slug":"oxynorm","indication":"Moderate to severe acute pain","status":"marketed"}]}],"pipeline":[{"name":"OxyNorm","genericName":"OxyNorm","slug":"oxynorm","phase":"marketed","mechanism":"OxyNorm is an immediate-release oral formulation of oxycodone that binds to opioid receptors in the central nervous system to provide rapid pain relief.","indications":["Moderate to severe acute pain","Breakthrough pain in opioid-tolerant patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQN0NyRTVVcGtWTUMzczl1ZDdCMWhEUDZHT1RsMVZSU1RvWk1mbS1Ldm4tOC15eWxsYzY2dlR0b0NpaHhCZFZJM2ZXT2NXc19VWG1WS3FZOTZlSVVRT3VKbE0weU1FU2ctUnJlb205cVU2c0JGaGIxU2g4M2VrWXJWVHZubk9BYlhTYW1JZEc1WHpxZzZq?oc=5","date":"2024-05-27","type":"pipeline","source":"Seeking Alpha","summary":"ATAI: Enormous Potential Upside But No Clarity Yet (NASDAQ:ATAI) - Seeking Alpha","headline":"ATAI: Enormous Potential Upside But No Clarity Yet (NASDAQ:ATAI)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}